Publications in collaboration with researchers from Memorial Sloan Kettering Cancer Center (23)

2024

  1. Effect of laterality on the postoperative survival of non-small cell lung cancer patients undergoing pneumonectomy

    Translational Lung Cancer Research, Vol. 13, Núm. 9, pp. 2411-2423

  2. Fine-mapping analysis including over 254,000 East Asian and European descendants identifies 136 putative colorectal cancer susceptibility genes

    Nature Communications, Vol. 15, Núm. 1

2023

  1. Author Correction: Deciphering colorectal cancer genetics through multi-omic analysis of 100,204 cases and 154,587 controls of European and east Asian ancestries (Nature Genetics, (2023), 55, 1, (89-99), 10.1038/s41588-022-01222-9)

    Nature Genetics

  2. Characterization and management of adverse events observed with mobocertinib (TAK-788) treatment for EGFR exon 20 insertion–positive non–small cell lung cancer

    Expert Review of Anticancer Therapy, Vol. 23, Núm. 1, pp. 95-106

  3. Deciphering colorectal cancer genetics through multi-omic analysis of 100,204 cases and 154,587 controls of European and east Asian ancestries

    Nature Genetics, Vol. 55, Núm. 1, pp. 89-99

  4. Mobocertinib (TAK-788) in EGFR Exon 20 Insertion+ Metastatic NSCLC: Patient-Reported Outcomes from EXCLAIM Extension Cohort

    Journal of Clinical Medicine, Vol. 12, Núm. 1

2022

  1. A randomised phase 2 study comparing different dose approaches of induction treatment of regorafenib in previously treated metastatic colorectal cancer patients (REARRANGE trial)

    European Journal of Cancer, Vol. 177, pp. 154-163

2021

  1. Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1

    Autophagy, Vol. 17, Núm. 1, pp. 1-382

  2. Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study

    The Lancet Oncology, Vol. 22, Núm. 2, pp. 212-222

  3. Treatment Outcomes and Safety of Mobocertinib in Platinum-Pretreated Patients with EGFR Exon 20 Insertion-Positive Metastatic Non-Small Cell Lung Cancer: A Phase 1/2 Open-label Nonrandomized Clinical Trial

    JAMA Oncology, Vol. 7, Núm. 12, pp. 1772-1781

2019

  1. Breast-implant associated anaplastic large-cell lymphoma. Consensus document (I). Epidemiology, pathogenesis, symptoms and diagnosis

    Revista de Senologia y Patologia Mamaria, Vol. 32, Núm. 2, pp. 61-66

  2. Corrigendum: Uniportal video-assisted thoracic surgery lobectomy: A consensus report from the Uniportal VATS Interest Group (UVIG) of the European Society of Thoracic Surgeons (ESTS) (European Journal of Cardio-thoracic Surgery (2019) 56 (224-229) DOI: 10.1093/ejcts/ezz133)

    European Journal of Cardio-thoracic Surgery

  3. Optimal Lymph Node Examination and Adjuvant Chemotherapy for Stage I Lung Cancer

    Journal of Thoracic Oncology, Vol. 14, Núm. 7, pp. 1277-1285

  4. Uniportal video-assisted thoracic surgery lobectomy: A consensus report from the Uniportal VATS Interest Group (UVIG) of the European Society of Thoracic Surgeons (ESTS)

    European Journal of Cardio-thoracic Surgery, Vol. 56, Núm. 2, pp. 224-229

2018

  1. Construction of a novel bispecific antibody to enhance antitumor activity against lung cancer

    Advanced Materials, Vol. 30, Núm. 51

2016

  1. Erratum to: Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition) (Autophagy, 12, 1, 1-222, 10.1080/15548627.2015.1100356

    Autophagy

  2. Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition)

    Autophagy, Vol. 12, Núm. 1, pp. 1-222

2014

  1. Phase I trial of olaparib in combination with cisplatin for the treatment of patients with advanced breast, ovarian and other solid tumors

    Annals of Oncology, Vol. 25, Núm. 8, pp. 1656-1663

  2. Predicting response and survival in chemotherapy-treated triple-negative breast cancer

    British Journal of Cancer, Vol. 111, Núm. 8, pp. 1532-1541

2011

  1. Pretreatment EGFR T790M Mutation and BRCA1 mRNA Expression in Erlotinib-Treated Advanced Non-Small-Cell Lung Cancer Patients with EGFR Mutations

    Clinical Cancer Research, Vol. 17, Núm. 5, pp. 1160-1168